NCT06534918 Precise Oncology Interventions in Nutrition and Training (OnPoint)
| NCT ID | NCT06534918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 306 participants |
| Start Date | 2024-09-18 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 306 participants in total. It began in 2024-09-18 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see if survivors of breast, prostate, or colorectal cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria - Healthcare Providers 1. Provide full- or part-time care in an oncology clinical care setting at Sylvester Comprehensive Cancer Center 2. Utilize the electronic medical record for patient documentation on a regular basis 3. Willing to complete a 30-60-minute interview Inclusion Criteria - Patients 1. 18 years of age or older 2. Any sex/gender 3. Able to provide consent 4. Able to read/understand English or Spanish 5. Diagnosis of breast, prostate or colorectal cancer, 6 months post completion of primary treatment, with no evidence of primary disease 6. Approval from treating oncologist, confirmed via email or in writing 7. Fail to meet at least one of the American Cancer Society guidelines: engaging in \>150 minutes of moderate-to-vigorous physical activity per week for the prior month or consuming at least 3 cups of vegetables and 2 cups of fruit per day over the past month. 8. Internet access on a smart phone, tablet, or computer 9. Agree to be randomly assigned to any study group Exclusion Criteria: 1. Less than 18 years of age 2. Unable to provide consent 3. Unable to read/understand English or Spanish 4. Any contraindication for diet change or exercising as determined by physician 5. Blank 6. Engaging in \>150 minutes of moderate to vigorous physical activity on average per week for the prior month 7. Meeting the American Cancer Society diet recommendations (3 cups of vegetables or legumes, 2 cups of fruit, 2 serving whole grain per day, and limited red/processed meats, sugar-sweetened beverages, and highly processed foods) for the prior month 8. History of dementia or major psychiatric disease which would interfere with study participation 9. History of recent (≤1 yr) stroke, myocardial infarction or congestive heart failure 10. Eastern Cooperative Oncology Group (ECOG) score of \>2 11. Severe lymphedema as determined by physician 12. Receiving physical therapy treatment
Contact & Investigator
Tracy Crane, PhD, RDN
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT06534918 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06534918 currently recruiting?
Yes, NCT06534918 is actively recruiting participants. Contact the research team at g.freylersythe@med.miami.edu for enrollment information.
Where is the NCT06534918 trial being conducted?
This trial is being conducted at Miami, United States.
Who is sponsoring the NCT06534918 clinical trial?
NCT06534918 is sponsored by University of Miami. The principal investigator is Tracy Crane, PhD, RDN at University of Miami. The trial plans to enroll 306 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.